Sigma-Aldrich to Acquire BioReliance for $350M | GenomeWeb

Sigma-Aldrich to Acquire BioReliance for $350M

Jan 09, 2012

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has signed an agreement to acquire BioReliance Holdings from Avista Capital Partners for $350 million in cash.

Rockville, Md.-based BioReliance provides biologic, specialized toxicology, and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science customers. The firm had full-year 2010 revenues of around $110 million and is expected to post double-digit growth for 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Related Articles

Sep 22, 2014

Merck KGaA to Buy Sigma-Aldrich for $17B

Jul 24, 2014

Sigma-Aldrich Q2 Sales Rise 3 Percent

Oct 23, 2014

Sigma-Aldrich Q3 Revenues Grow 4 Percent

Feb 12, 2015

Sigma-Aldrich Q4 Revenues Increase 3 Percent Despite Negative Currency Effects

Apr 24, 2014

Sigma-Aldrich Q1 Sales up 2 Percent

Dec 23, 2014

Merck KGaA's $17B Buy of Sigma-Aldrich Clears US Regulators

Breaking News

The Scan

This Week in Nature

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Bits of Evidence

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Return on Microbiome Research

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus to Leave NCI

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.